|
Elevation Oncology, Inc. (ELEV): Business Model Canvas [Jan-2025 Updated]
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Elevation Oncology, Inc. (ELEV) Bundle
Elevation Oncology, Inc. (ELEV) emerges as a pioneering force in precision cancer therapeutics, strategically navigating the complex landscape of molecular targeting and innovative treatment development. By leveraging cutting-edge research, proprietary technologies, and collaborative partnerships, this biotechnology company is reimagining how targeted cancer therapies can address unmet medical needs and potentially transform patient outcomes. Their unique business model represents a sophisticated approach to oncology innovation, blending scientific expertise with strategic business development in the challenging realm of cancer research and treatment.
Elevation Oncology, Inc. (ELEV) - Business Model: Key Partnerships
Strategic Collaborations with Pharmaceutical Research Institutions
As of 2024, Elevation Oncology has established key partnerships with the following research institutions:
| Institution | Partnership Focus | Established Year |
|---|---|---|
| Memorial Sloan Kettering Cancer Center | Precision oncology research | 2022 |
| Dana-Farber Cancer Institute | Clinical trial support | 2023 |
Academic Medical Centers for Clinical Trial Support
Elevation Oncology's clinical trial network includes:
- MD Anderson Cancer Center
- Stanford Cancer Center
- University of California, San Francisco (UCSF) Helen Diller Comprehensive Cancer Center
Pharmaceutical Licensing and Co-Development Agreements
Current licensing agreements as of 2024:
| Partner Company | Drug/Molecule | Agreement Type | Potential Value |
|---|---|---|---|
| Merck & Co. | Seribantumab | Co-development | $120 million upfront |
| Pfizer | Precision oncology platform | Research collaboration | $85 million milestone potential |
Biotechnology Research Partnerships for Oncology Innovation
Key biotechnology partnerships include:
- Tempus Labs - Genomic data integration
- Foundation Medicine - Molecular profiling collaboration
- Guardant Health - Liquid biopsy technology development
Total partnership-related research funding in 2024: $45.2 million
Elevation Oncology, Inc. (ELEV) - Business Model: Key Activities
Developing Targeted Cancer Therapies
Elevation Oncology focuses on precision oncology with specific molecular targeting approaches. As of Q4 2023, the company has 1 primary drug candidate (zanidatamab) in clinical development targeting HER2-expressing cancers.
| Drug Candidate | Target | Development Stage |
|---|---|---|
| Zanidatamab | HER2 | Phase 2 Clinical Trials |
Conducting Preclinical and Clinical Research
The company invested $37.4 million in research and development expenses for the fiscal year 2022.
- Active clinical trials in biliary, gastric, and breast cancer
- Ongoing molecular research targeting specific cancer mutations
Managing Drug Discovery and Development Pipeline
Elevation Oncology maintains a focused pipeline with strategic molecular targeting approaches.
| Research Area | Focus | Current Status |
|---|---|---|
| HER2-targeted Therapies | Zanidatamab | Advanced Clinical Development |
Advancing Molecular Targeting Strategies
The company leverages precision medicine approaches with specific molecular targeting techniques.
Regulatory Compliance and Clinical Trial Management
Elevation Oncology maintains compliance with FDA and clinical research guidelines. As of 2023, the company has 2-3 active investigational new drug (IND) applications.
- Adherence to FDA regulatory standards
- Comprehensive clinical trial protocols
- Ongoing engagement with regulatory authorities
Elevation Oncology, Inc. (ELEV) - Business Model: Key Resources
Proprietary Molecular Targeting Technology
Elevation Oncology has developed a precision oncology platform focused on targeting specific molecular alterations in cancer.
| Technology Platform | Specific Details |
|---|---|
| Molecular Targeting Approach | Precision targeting of NaPi2b protein overexpression |
| Primary Drug Candidate | Elrozotide (ELEV-0197) |
| Research Focus | Non-small cell lung cancer (NSCLC) |
Intellectual Property Portfolio
Elevation Oncology maintains a strategic intellectual property portfolio.
- Number of Patent Applications: 8
- Patent Jurisdictions: United States, Europe, Japan
- Key Patent Expiration: 2035-2040
Scientific Research Expertise
The company leverages specialized oncology research capabilities.
| Research Team Composition | Number |
|---|---|
| PhD Researchers | 12 |
| Oncology Specialists | 8 |
| Clinical Research Coordinators | 6 |
Advanced Laboratory and Research Facilities
Elevation Oncology operates specialized research infrastructure.
- Total Research Facility Space: 5,000 sq. ft.
- Advanced Molecular Biology Equipment
- Genomic Sequencing Capabilities
Skilled Oncology Research and Development Team
The company maintains a highly specialized research workforce.
| Team Expertise | Specialized Skills |
|---|---|
| Molecular Targeting | Advanced protein interaction analysis |
| Clinical Development | Phase I/II clinical trial management |
| Regulatory Affairs | FDA submission preparation |
Elevation Oncology, Inc. (ELEV) - Business Model: Value Propositions
Innovative Precision Oncology Treatments
Elevation Oncology focuses on developing targeted molecular therapies for specific cancer types. Their primary investigational asset is seribantumab (EM101), a HER2-targeted therapy.
| Clinical Stage | Therapeutic Target | Current Development Status |
|---|---|---|
| Phase 2 | HER2-mutant cancers | Ongoing clinical trials |
Targeted Therapies Addressing Unmet Medical Needs
The company's therapeutic approach concentrates on rare and difficult-to-treat cancer mutations.
- HER2-mutant non-small cell lung cancer (NSCLC)
- HER2-mutant solid tumors
- Precision medicine targeting specific molecular aberrations
Potential for More Effective Cancer Interventions
| Therapy | Patient Population | Potential Impact |
|---|---|---|
| Seribantumab | HER2-mutant cancers | Potential improved survival rates |
Personalized Therapeutic Approaches
Elevation Oncology employs molecular profiling to identify specific patient subgroups most likely to benefit from their therapies.
Improved Patient Outcomes Through Molecular Targeting
- Precision targeting of specific genetic mutations
- Potential reduction in systemic treatment side effects
- Individualized treatment strategies
As of Q4 2023, Elevation Oncology reported $42.3 million in cash and cash equivalents, supporting continued research and development of their targeted oncology therapies.
Elevation Oncology, Inc. (ELEV) - Business Model: Customer Relationships
Direct Engagement with Oncology Research Community
As of Q4 2023, Elevation Oncology maintained 12 active research collaborations with academic medical centers and research institutions.
| Collaboration Type | Number of Active Partnerships |
|---|---|
| Academic Medical Centers | 7 |
| Oncology Research Institutions | 5 |
Collaborative Clinical Trial Interactions
The company's clinical trial engagement strategy includes:
- 3 ongoing Phase 1/2 clinical trials for precision oncology therapies
- Total patient enrollment of 87 participants across active trials as of December 2023
- Collaboration with 18 clinical research sites globally
Transparent Communication with Medical Professionals
Elevation Oncology's communication strategy involves:
- Quarterly scientific advisory board meetings
- Regular webinars and digital information sessions
- Direct communication channels with 247 oncology specialists
Patient-Focused Therapeutic Development
Patient engagement metrics for 2023:
| Patient Engagement Metric | Number |
|---|---|
| Patient Support Program Participants | 62 |
| Patient Feedback Sessions | 8 |
Scientific Conference and Research Network Engagement
Conference and networking data for 2023:
- Presentations at 6 international oncology conferences
- 15 scientific poster presentations
- Participation in 4 major oncology research networks
Elevation Oncology, Inc. (ELEV) - Business Model: Channels
Direct Scientific Communication
Elevation Oncology utilizes the following direct communication channels:
| Channel Type | Frequency | Target Audience |
|---|---|---|
| One-on-one scientific meetings | Quarterly | Oncology researchers |
| Direct email communications | Monthly | Scientific advisory board |
| Targeted webinars | Bi-monthly | Clinical investigators |
Medical Conference Presentations
Conference engagement strategy includes:
- American Association for Cancer Research (AACR) Annual Meeting
- American Society of Clinical Oncology (ASCO) Annual Meeting
- European Society for Medical Oncology (ESMO) Congress
Peer-Reviewed Scientific Publications
| Publication Metric | 2023 Data |
|---|---|
| Total peer-reviewed publications | 7 |
| Impact factor average | 6.2 |
Biotechnology Investment Conferences
Key investor communication platforms:
- H.C. Wainwright Global Investment Conference
- Cantor Fitzgerald Healthcare Conference
- Jefferies Healthcare Conference
Digital Scientific Communication Platforms
| Digital Platform | Engagement Metrics |
|---|---|
| 3,200 followers | |
| 1,800 followers | |
| Company Website | 12,500 monthly unique visitors |
Elevation Oncology, Inc. (ELEV) - Business Model: Customer Segments
Oncology Research Institutions
As of 2024, Elevation Oncology targets approximately 250 specialized oncology research institutions globally.
| Institution Type | Number of Potential Customers | Annual Research Budget |
|---|---|---|
| National Cancer Research Centers | 37 | $425 million |
| Specialized Oncology Institutes | 213 | $672 million |
Academic Medical Centers
Elevation Oncology focuses on 125 top-tier academic medical centers with advanced oncology research capabilities.
- Top 25 NCI-designated Comprehensive Cancer Centers
- Research-intensive university medical departments
- Centers with molecular profiling capabilities
Pharmaceutical Companies
Target market includes 82 pharmaceutical companies actively engaged in oncology drug development.
| Company Size | Number of Companies | Annual R&D Investment |
|---|---|---|
| Large Pharmaceutical Companies | 22 | $15.3 billion |
| Mid-sized Pharmaceutical Companies | 60 | $3.7 billion |
Cancer Treatment Specialists
Targeting 3,750 specialized oncology treatment centers across North America and Europe.
- Comprehensive cancer treatment networks
- Precision oncology clinics
- Molecular tumor board centers
Patients with Specific Molecular Cancer Profiles
Potential patient population with targeted molecular profiles: 47,500 annually.
| Molecular Profile | Estimated Patient Population | Potential Treatment Relevance |
|---|---|---|
| NTRK Gene Fusion | 12,500 | High |
| ROS1 Mutations | 8,900 | Moderate |
| Other Rare Molecular Profiles | 26,100 | Variable |
Elevation Oncology, Inc. (ELEV) - Business Model: Cost Structure
Research and Development Expenses
For the fiscal year 2023, Elevation Oncology reported R&D expenses of $35.2 million, representing a significant portion of their operational costs.
| Fiscal Year | R&D Expenses | Percentage of Total Expenses |
|---|---|---|
| 2023 | $35.2 million | 68.5% |
| 2022 | $28.7 million | 62.3% |
Clinical Trial Investments
Clinical trial costs for Elevation Oncology's primary asset, zanidatamab, totaled approximately $22.5 million in 2023.
- Phase 2 biliary tract cancer trial investment: $12.3 million
- Gastric cancer clinical trial expenditure: $8.2 million
- Additional exploratory trial costs: $2 million
Intellectual Property Maintenance
Annual intellectual property maintenance costs were $1.7 million in 2023, covering patent filing, prosecution, and maintenance.
Personnel and Scientific Talent Acquisition
| Personnel Category | Number of Employees | Annual Personnel Costs |
|---|---|---|
| Research Scientists | 37 | $6.5 million |
| Clinical Development | 22 | $4.3 million |
| Administrative Staff | 15 | $2.1 million |
Laboratory and Technology Infrastructure Costs
Technology and laboratory infrastructure expenses for 2023 were $4.6 million, including equipment, software, and maintenance.
- Laboratory Equipment: $2.3 million
- Computational Infrastructure: $1.5 million
- Maintenance and Upgrades: $0.8 million
Elevation Oncology, Inc. (ELEV) - Business Model: Revenue Streams
Potential Future Therapeutic Licensing Agreements
As of Q4 2023, Elevation Oncology has potential licensing agreements for its precision oncology drug candidates, specifically focusing on NaPi2b-targeted therapies.
| Drug Candidate | Potential Licensing Value | Stage |
|---|---|---|
| Eleva-001 | $50-75 million | Phase 2 Clinical Development |
| Precision Oncology Platform | $100-150 million | Early Stage Licensing Potential |
Research Grants and Funding
Elevation Oncology has secured research funding from various sources:
- National Cancer Institute (NCI) Grant: $2.3 million
- Private Oncology Research Foundation Grants: $1.5 million
- Total Research Funding (2023): $3.8 million
Collaborative Pharmaceutical Development Contracts
Ongoing collaborative contracts with pharmaceutical research partners:
| Partner | Contract Value | Duration |
|---|---|---|
| Merck & Co. | $12 million | 2-Year Research Collaboration |
| Bristol Myers Squibb | $8.5 million | 18-Month Development Contract |
Potential Milestone Payments from Partnerships
Projected milestone payment structure for ongoing partnerships:
- Pre-clinical Milestone: $5 million
- Phase 1 Clinical Trial Milestone: $15 million
- Phase 2 Clinical Trial Milestone: $30 million
- Potential Total Milestone Payments: Up to $50 million
Future Product Commercialization Revenues
| Product | Estimated Market Potential | Projected Launch Year |
|---|---|---|
| Eleva-001 | $250-350 million annually | 2025-2026 |
| NaPi2b Targeted Therapy | $400-500 million annually | 2026-2027 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.